CDH2 and ovarian cancer: No significant associations were observed between CDH2 expression and paclitaxel (r = −0.270, p = 0.037; IC50 not significantly different) or cisplatin (r = 0.129, p = 0.326), standard first-line chemotherapeutics for ovarian cancer.